The International Workshop on Clinical Pharmacology of Tuberculosis Drugs collaborates with a committed group of international experts in the field of clinical pharmacology of tuberculosis drugs. By working together with our extensive global network of experts from various backgrounds in the field, we aim to deliver the most relevant and state-of-the-art program.
Meeting category
Date(s)
10 Sep 2019
Program Language
English
Location
London,
United Kingdom
Organizer
International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019
Related Enduring Materials
Enduring Materials
Tuesday, 10 September 2019
- 08:30
08:30 BST
Workshop Opening
Rob Aarnoutse, PharmD, PhD
Radboud University Medical Center, The Netherlands
Session 1: Pharmacokinetics and Pharmacodynamics of New and Repurposed TB Drugs - 08:45
08:45 BST
Oxazolidinones for TB: Current Status and Future Prospects
Discussion
09:15 BST
Oral Abstract Presentations
Evaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients
Lénaïg Tanneau
Relationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB
Precious Ngwalero
Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial
Dr. Elisa Ignatius
Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB
Dr. Ahmed Aliyu Abulfathi
10:15 BST
Discussion
Session 2: Pharmacokinetics and Pharmacodynamics of Established TB Drugs - 11:00
11:00 BST
Oral Abstract Presentations
Pharmacogenetics and Pharmacokinetics of First-Line Anti-Tuberculosis Drugs in the HIRIF Trial
Dr. Elizabeth Mackay
Increased Bactericidal Activity but Dose-Limiting Tolerability at 50 mg/kg Rifampicin
Dr. Lindsey Te Brake
Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis
Dr. Charles Peloquin
Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial
Dr. Chishala Chabala
The OptiRIF Study: Pharmacokinetics of High-Dose Rifampicin in Children
Dr. Elin Svensson
12:15 BST
Discussion
13:15 BST
Guided Poster Session
Chair: Charles Peloquin, PharmD
University of Florida, United States
Mechanistic Modelling of Time-to-Positivity and Colony-Forming Unit in Tuberculosis Patients on High-Dose Rifampicin to Improve Understanding of Biomarker Relation
Ahmad Rami Ayoun Alsoud
Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Dr. Elin Svensson
Optimal Dose Individualisation of Rifampicin needs to Account for Between-Occasion Variability
Lina Keutzer
Levofloxacin Urine Kinetics and Development of a Colorimetric Assay for Therapeutic Drug Monitoring Among People Living with HIV and TB
Daniel Van Aartsen
Mathematical Modeling using In Vitro Checkerboard Assay Data: Clofazimine as a Potentially Synergistic Anti-TB Drug
Dr. Charles Peloquin
Comparison of a Bayesian Forecasting Algorithm Handling Inter-Occasion Variability and a Linear Regression Approach for Dose Individualization of Rifampicin
Selma El Messaoud
Protein Binding Determination of Second-Line Anti-Tuberculosis Drugs In Vitro using an Ultrafiltration Technique
Dr. Charles Peloquin
Session 3: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Modelling - 14:00
14:00 BST
Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO
Discussion
14:30 BST
Oral Abstract Presentations
Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis
Dr. Frank Kloprogge
PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312
Kamunkhwala Gausi
Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis
Dr. Charles Peloquin
Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM
Dr. Mathieu Bolhuis
15:30 BST
Discussion
Session 4: TB Drug Development and Optimization: Approaches and Tools - 16:15
16:15 BST
Combined use of Biomarker Data and Drug Exposures to Predict TB Treatment Response
Discussion
16:45 BST
An Assay to Measure Drug Tolerance of M. Tuberculosis in the Caseous Center of Pulmonary Lesions
Jansy Sarathy
-
17:00 BST
A PBPK Modelling Approach to Simulate the Rifampicin-Moxifloxacin Drug-Drug Interaction in TB Patients
Carlijn Litjens
-
17:15 BST
Stratified Dosage Regimens from Early Bactericidal Activity Studies: An Application to Pretomanid
Dr. Michael Lyons
-
17:30 BST
Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients
17:45 BST
Discussion
18:00 BST
Closure and Adjournment
Overview
Welcome
We are proud to announce the 12th edition of the International Workshop on Pharmacology of Tuberculosis Drugs! This year's edition is scheduled for 10 September and will take place in London, UK.
The treatment of tuberculosis (TB) is becoming a challenge worldwide. All around the world, experts in the field are involved in intensive research to be able to cope with the various concerns regarding treatment.
The aim of this abstract-driven workshop is to make a significant contribution to the optimization of TB treatment by bringing experts together and having them present and discuss the latest important scientific findings in the TB clinical pharmacology field. Additionally, scientific, regulatory or strategy issues that are highly relevant to the optimization of TB treatment will be exchanged and discussed.
General Information
Meeting Objectives
- To gather experts involved in the pharmacology of TB drugs from different disciplines in an interactive workshop setting
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB
- To provide a platform for presentation and discussion of the latest scientific developments in the field.
- To map all current studies and results related to available and new TB drugs
- To help translate new in vitro and in vivo pharmacological data into new drug treatment combinations for TB
Unique Features
Our workshop involves a strong community of clinical pharmacologists and other healthcare professionals working in the TB-field. Also, the workshop provides an independent scientific platform to discuss controversial topics and views.
Practical Information
Certificate of Attendance
A digital certificate of attendance was sent to participants in the week following the workshop.
Language
The official workshop language was English.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Expert Medical Events, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Expert Medical Events disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Photograph, Audio and Video Recording
Photographs as well as audio and video recordings are not permitted during official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted on the workshop website as soon as possible following the workshop, provided the speaker has given us permission to use their presentation online.
Committees
Organizing Committee
The members of the Organizing Committee (OC) discuss, on a frequent basis, the scientific program of the workshop, identify interesting topics and candidate speakers and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee assist the OC by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee actively participate in reviewing submitted abstracts.
- Jan-Willem Alffenaar, PhD, PharmD UMCG, The Netherlands
- Deron Burton CDC, USA
- Dakshina Chilukuri, PhD FDA, USA
- Véronique Dartois, PhD Rutgers, The State University of New Jersey, Newark, USA
- Paolo Denti, PhD University of Cape Town, South Africa
- Kelly Dooley, MD, PhD Johns Hopkins University, USA
- Tawanda Gumbo, MD Baylor Institute for Immunology Research, USA
- Richard Hafner, MD National Institutes of Health, USA
- Scott Heysell, MD, MPH University of Virginia, USA
- Anneke Hesseling, MD Desmond Tutu Tuberculosis Centre, South Africa
- Russell Kempker, MD, MSc Emory University School of Medicine, USA
- Steven Kern, PhD Bill & Melinda Gates Foundation, USA
- Christian Lienhardt, MD, PhD WHO – Stop TB Department, Switzerland
- Khisi Mdluli, PhD Global Alliance for TB Drug Development, USA
- Rovina Ruslami, MD, PhD Padjadjaran University, Indonesia
- Ulrika Simonsson, PharmD, PhD Uppsala University, Sweden
- Susan Swindells, MBBS University of Nebraska Medical Center, USA
- Andrew Vernon, MD CDC, TBTC, USA
- Robert Wallis, MD, FIDSA The Aurum Institute, South Africa
Support
Endorsers
Endorsers
